





Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(USE AS MANY SHEETS AS NECESSARY)

Sheet 1 of 3

<b>Confirmation Number</b>	9072
<b>Application Number</b>	10/810,755
<b>Filing Date</b>	03/26/2004
<b>First Named Inventor</b>	Michael J. Renzi
<b>Group Art Unit</b>	1649
<b>Examiner Name</b>	E.M. Kobern
<b>Attorney Docket Number</b>	PRD2052USNP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
RS		Brines et al., "Erythropoietin Crosses The Blood-Brain Barrier To Protect Against Experimental Brain Injury", <i>P.N.A.S. U S A</i> (2000) 97:10526-10531	
		Campana WM, et al., Identification of a neurotrophic sequence in erythropoietin. <i>Int J Mol Med.</i> 1998;1:235-241	
		Celik M, et. al., Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. <i>Proc Natl Acad Sci U S A.</i> 2002;99:2258-2263	
		Cerami A, et. al., Effects of epoetin alfa on the central nervous system. <i>Semin Oncol.</i> 2001;28:66-70.	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/30/07
-----------------------	--------------------	--------------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Confirmation Number	9072
Application Number	10/810,755
Filing Date	03/26/2004
First Named Inventor	Michael J. Renzi
Group Art Unit	1646 1647
Examiner Name	R.M. DeBery

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
RO		Ehrenreich H, et. al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.	
		Gorio A, et. al., Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99:9450-9455.	
		Hernandez TD, et al., Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324	
		Junk AR, et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659-10664.	
		Masuda S, et al., A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493	
		Morishita et al., "Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevents In Vitro Glutamate-Induced Neuronal Death", Neuroscience (1997) 76:105-116	
		Nagai A, et al., Erythropoietin and erythropoietin receptors in human cns neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386-392	
		Priller J, et. al., Inflammation in stroke--a potential target for neuroprotection? Ernst Schering Res Found Workshop. 2002:133-157	
		Ruscher K, et. al., Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.	
		Silva M, et al., Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-xl and bcl-2. Blood. 1996;88:1576-1582	
		Siren AL, et al., Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271-276	
		Siren AL, et. al., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98:4044-4049.	
		Wen TC, et. al., Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating bcl-xl expression. J Neurosci Res. 2002;67:795-803	
		Zimmerman GA, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92:3744-3748	
		Bernaudin, Myriam, et al, A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice, Journal of Cerebral Blood flow and Metabolism, 1999, 19-643-651	
		Digicayiloglu, M. et al, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kB signaling cascades, Nature 2001 Vol. 412	
MD		Juul, Sandra, Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System, Pediatric Research, 1998, Vol. 43 No 1	
		Koshimura, K. et al, Effects of Erythropoietin on Neuronal Activity, Journal of Neurochemistry, 1999	

Examiner Signature	R.M. DeBery	Date Considered	4/30/07
-----------------------	-------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

